Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.27, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 528.92K shares, decreasing 67.34% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.03.